Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster

Jorge Reyes-del Valle, Cynthia de la Fuente, Mallory A. Turner, Christoph Springfeld, Swapna Apte-Sengupta, Marie E. Frenzke, Amelie Forest, Jillian Whidby, Joseph Marcotrigiano, Charles M. Rice, Roberto Cattaneo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection remains a serious public health problem worldwide. Treatments are limited, and no preventive vaccine is available. Toward developing an HCV vaccine, we engineered two recombinant measles viruses (MVs) expressing structural proteins from the prototypic HCV subtype 1a strain H77. One virus directs the synthesis of the HCV capsid (C) protein and envelope glycoproteins (E1 and E2), which fold properly and form a heterodimer. The other virus expresses the E1 and E2 glycoproteins separately, with each one fused to the cytoplasmic tail of the MV fusion protein. Although these hybrid glycoproteins were transported to the plasma membrane, they were not incorporated into MV particles. Immunization of MV-susceptible, genetically modified mice with either vector induced neutralizing antibodies to MV and HCV. A boost with soluble E2 protein enhanced titers of neutralizing antibody against the homologous HCV envelope. In animals primed with MV expressing properly folded HCV C-E1-E2, boosting also induced cross-neutralizating antibodies against two heterologous HCV strains. These results show that recombinant MVs retain the ability to induce MV-specific humoral immunity while also eliciting HCV neutralizing antibodies, and that anti-HCV immunity can be boosted with a single dose of purified E2 protein. The use of MV vectors could have advantages for pediatric HCV vaccination.

Original languageEnglish (US)
Pages (from-to)11558-11566
Number of pages9
JournalJournal of Virology
Volume86
Issue number21
DOIs
StatePublished - Nov 2012

Fingerprint

Measles virus
Hepatitis C virus
Recombinant Proteins
neutralization
Hepacivirus
immune response
proteins
Neutralizing Antibodies
Viral Fusion Proteins
neutralizing antibodies
Glycoproteins
glycoproteins
Vaccines
viral fusion proteins
Viruses
Viral Structural Proteins
vaccines
Hepatitis C Antibodies
viruses
Capsid Proteins

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. / Reyes-del Valle, Jorge; de la Fuente, Cynthia; Turner, Mallory A.; Springfeld, Christoph; Apte-Sengupta, Swapna; Frenzke, Marie E.; Forest, Amelie; Whidby, Jillian; Marcotrigiano, Joseph; Rice, Charles M.; Cattaneo, Roberto.

In: Journal of Virology, Vol. 86, No. 21, 11.2012, p. 11558-11566.

Research output: Contribution to journalArticle

Reyes-del Valle, J, de la Fuente, C, Turner, MA, Springfeld, C, Apte-Sengupta, S, Frenzke, ME, Forest, A, Whidby, J, Marcotrigiano, J, Rice, CM & Cattaneo, R 2012, 'Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster', Journal of Virology, vol. 86, no. 21, pp. 11558-11566. https://doi.org/10.1128/JVI.01776-12
Reyes-del Valle, Jorge ; de la Fuente, Cynthia ; Turner, Mallory A. ; Springfeld, Christoph ; Apte-Sengupta, Swapna ; Frenzke, Marie E. ; Forest, Amelie ; Whidby, Jillian ; Marcotrigiano, Joseph ; Rice, Charles M. ; Cattaneo, Roberto. / Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. In: Journal of Virology. 2012 ; Vol. 86, No. 21. pp. 11558-11566.
@article{db391200c4d644aa8ab5fad9af10c346,
title = "Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster",
abstract = "Hepatitis C virus (HCV) infection remains a serious public health problem worldwide. Treatments are limited, and no preventive vaccine is available. Toward developing an HCV vaccine, we engineered two recombinant measles viruses (MVs) expressing structural proteins from the prototypic HCV subtype 1a strain H77. One virus directs the synthesis of the HCV capsid (C) protein and envelope glycoproteins (E1 and E2), which fold properly and form a heterodimer. The other virus expresses the E1 and E2 glycoproteins separately, with each one fused to the cytoplasmic tail of the MV fusion protein. Although these hybrid glycoproteins were transported to the plasma membrane, they were not incorporated into MV particles. Immunization of MV-susceptible, genetically modified mice with either vector induced neutralizing antibodies to MV and HCV. A boost with soluble E2 protein enhanced titers of neutralizing antibody against the homologous HCV envelope. In animals primed with MV expressing properly folded HCV C-E1-E2, boosting also induced cross-neutralizating antibodies against two heterologous HCV strains. These results show that recombinant MVs retain the ability to induce MV-specific humoral immunity while also eliciting HCV neutralizing antibodies, and that anti-HCV immunity can be boosted with a single dose of purified E2 protein. The use of MV vectors could have advantages for pediatric HCV vaccination.",
author = "{Reyes-del Valle}, Jorge and {de la Fuente}, Cynthia and Turner, {Mallory A.} and Christoph Springfeld and Swapna Apte-Sengupta and Frenzke, {Marie E.} and Amelie Forest and Jillian Whidby and Joseph Marcotrigiano and Rice, {Charles M.} and Roberto Cattaneo",
year = "2012",
month = "11",
doi = "10.1128/JVI.01776-12",
language = "English (US)",
volume = "86",
pages = "11558--11566",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

TY - JOUR

T1 - Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster

AU - Reyes-del Valle, Jorge

AU - de la Fuente, Cynthia

AU - Turner, Mallory A.

AU - Springfeld, Christoph

AU - Apte-Sengupta, Swapna

AU - Frenzke, Marie E.

AU - Forest, Amelie

AU - Whidby, Jillian

AU - Marcotrigiano, Joseph

AU - Rice, Charles M.

AU - Cattaneo, Roberto

PY - 2012/11

Y1 - 2012/11

N2 - Hepatitis C virus (HCV) infection remains a serious public health problem worldwide. Treatments are limited, and no preventive vaccine is available. Toward developing an HCV vaccine, we engineered two recombinant measles viruses (MVs) expressing structural proteins from the prototypic HCV subtype 1a strain H77. One virus directs the synthesis of the HCV capsid (C) protein and envelope glycoproteins (E1 and E2), which fold properly and form a heterodimer. The other virus expresses the E1 and E2 glycoproteins separately, with each one fused to the cytoplasmic tail of the MV fusion protein. Although these hybrid glycoproteins were transported to the plasma membrane, they were not incorporated into MV particles. Immunization of MV-susceptible, genetically modified mice with either vector induced neutralizing antibodies to MV and HCV. A boost with soluble E2 protein enhanced titers of neutralizing antibody against the homologous HCV envelope. In animals primed with MV expressing properly folded HCV C-E1-E2, boosting also induced cross-neutralizating antibodies against two heterologous HCV strains. These results show that recombinant MVs retain the ability to induce MV-specific humoral immunity while also eliciting HCV neutralizing antibodies, and that anti-HCV immunity can be boosted with a single dose of purified E2 protein. The use of MV vectors could have advantages for pediatric HCV vaccination.

AB - Hepatitis C virus (HCV) infection remains a serious public health problem worldwide. Treatments are limited, and no preventive vaccine is available. Toward developing an HCV vaccine, we engineered two recombinant measles viruses (MVs) expressing structural proteins from the prototypic HCV subtype 1a strain H77. One virus directs the synthesis of the HCV capsid (C) protein and envelope glycoproteins (E1 and E2), which fold properly and form a heterodimer. The other virus expresses the E1 and E2 glycoproteins separately, with each one fused to the cytoplasmic tail of the MV fusion protein. Although these hybrid glycoproteins were transported to the plasma membrane, they were not incorporated into MV particles. Immunization of MV-susceptible, genetically modified mice with either vector induced neutralizing antibodies to MV and HCV. A boost with soluble E2 protein enhanced titers of neutralizing antibody against the homologous HCV envelope. In animals primed with MV expressing properly folded HCV C-E1-E2, boosting also induced cross-neutralizating antibodies against two heterologous HCV strains. These results show that recombinant MVs retain the ability to induce MV-specific humoral immunity while also eliciting HCV neutralizing antibodies, and that anti-HCV immunity can be boosted with a single dose of purified E2 protein. The use of MV vectors could have advantages for pediatric HCV vaccination.

UR - http://www.scopus.com/inward/record.url?scp=84869061330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869061330&partnerID=8YFLogxK

U2 - 10.1128/JVI.01776-12

DO - 10.1128/JVI.01776-12

M3 - Article

VL - 86

SP - 11558

EP - 11566

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

ER -